TheStreet Lowers BioTime (NYSEAMERICAN:BTX) to D

TheStreet cut shares of BioTime (NYSEAMERICAN:BTX) from a c rating to a d rating in a research note published on Monday, April 9th.

Several other research analysts have also commented on BTX. Zacks Investment Research lowered shares of BioTime from a hold rating to a sell rating in a report on Friday, January 12th. Lake Street Capital initiated coverage on shares of BioTime in a research note on Friday, February 2nd. They set a buy rating and a $8.00 price objective on the stock. Three research analysts have rated the stock with a sell rating and two have assigned a buy rating to the company. The stock has a consensus rating of Hold and an average target price of $5.75.

How to Become a New Pot Stock Millionaire

Shares of BTX opened at $2.38 on Monday. BioTime has a 52-week low of $2.10 and a 52-week high of $3.50.

BioTime (NYSEAMERICAN:BTX) last issued its quarterly earnings data on Thursday, March 15th. The biotechnology company reported ($0.08) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.02). BioTime had a net margin of 828.55% and a return on equity of 30.68%. The business had revenue of $1.00 million during the quarter, compared to analyst estimates of $2.38 million.

A number of institutional investors have recently added to or reduced their stakes in BTX. Dimensional Fund Advisors LP boosted its holdings in BioTime by 29.8% in the third quarter. Dimensional Fund Advisors LP now owns 156,721 shares of the biotechnology company’s stock worth $445,000 after purchasing an additional 35,970 shares during the period. Jane Street Group LLC boosted its holdings in BioTime by 95.6% in the third quarter. Jane Street Group LLC now owns 44,548 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 21,778 shares during the period. GSA Capital Partners LLP boosted its holdings in BioTime by 124.1% in the third quarter. GSA Capital Partners LLP now owns 174,816 shares of the biotechnology company’s stock worth $496,000 after purchasing an additional 96,816 shares during the period. Schwab Charles Investment Management Inc. boosted its holdings in shares of BioTime by 36.4% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 143,800 shares of the biotechnology company’s stock valued at $310,000 after acquiring an additional 38,400 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in shares of BioTime by 402.4% during the fourth quarter. SG Americas Securities LLC now owns 62,301 shares of the biotechnology company’s stock valued at $134,000 after acquiring an additional 49,900 shares during the period.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://ledgergazette.com/2018/04/20/biotime-btx-downgraded-to-d-at-thestreet.html.

About BioTime

BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy.

Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply